PH24377A - Formulations suitable for the stabilisation of alpha-interferon - Google Patents

Formulations suitable for the stabilisation of alpha-interferon

Info

Publication number
PH24377A
PH24377A PH34815A PH34815A PH24377A PH 24377 A PH24377 A PH 24377A PH 34815 A PH34815 A PH 34815A PH 34815 A PH34815 A PH 34815A PH 24377 A PH24377 A PH 24377A
Authority
PH
Philippines
Prior art keywords
active ingredient
alpha
stabilisation
interferon
formulations suitable
Prior art date
Application number
PH34815A
Inventor
Helmut Dr Franz
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of PH24377A publication Critical patent/PH24377A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The pharmaceutical forms are intended for topical administration and employ as vehicle for and stabiliser of the active ingredient a composition which specifically confers special stability on the active ingredient IFN alpha. The forms are essentially composed of hydroxyethylcellulose and gelatin and preferably contain highly purified IFN alpha which has been prepared by DNA recombination as active ingredient.
PH34815A 1986-02-05 1987-02-05 Formulations suitable for the stabilisation of alpha-interferon PH24377A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863603444 DE3603444A1 (en) 1986-02-05 1986-02-05 PHARMACEUTICAL PREPARATIONS FOR STABILIZING INTERFERON ALPHA

Publications (1)

Publication Number Publication Date
PH24377A true PH24377A (en) 1990-06-13

Family

ID=6293372

Family Applications (1)

Application Number Title Priority Date Filing Date
PH34815A PH24377A (en) 1986-02-05 1987-02-05 Formulations suitable for the stabilisation of alpha-interferon

Country Status (20)

Country Link
EP (1) EP0231816B1 (en)
JP (1) JPS62209024A (en)
KR (1) KR870007698A (en)
AT (1) ATE63823T1 (en)
AU (1) AU601712B2 (en)
CA (1) CA1295242C (en)
DD (1) DD284602A5 (en)
DE (2) DE3603444A1 (en)
DK (1) DK164202C (en)
ES (1) ES2028796T3 (en)
FI (1) FI86144C (en)
GR (1) GR3002270T3 (en)
HU (1) HU196560B (en)
IE (1) IE59697B1 (en)
IL (1) IL81472A0 (en)
NO (1) NO169638C (en)
NZ (1) NZ219169A (en)
PH (1) PH24377A (en)
PT (1) PT84243B (en)
ZA (1) ZA87793B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5275804A (en) * 1986-02-25 1994-01-04 E. B. Michaels Research Associates, Inc. Process and composition for oral hygiene
DE3731255A1 (en) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilization of therapeutically active proteins in pharmaceutical preparations
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3803312A1 (en) * 1988-02-04 1989-08-10 Gerd Prof Dr Med Gross Use of an interferon-containing gel
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
WO1989010756A1 (en) * 1988-05-06 1989-11-16 Toray Industries, Inc. STABLE INTERFERON beta COMPOSITION
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
US5244652A (en) * 1991-03-22 1993-09-14 E. B. Michaels Research Associates, Inc. Viscous surface active composition
US5863530A (en) * 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
WO1993006856A1 (en) * 1991-10-11 1993-04-15 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
FI106465B (en) * 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Process for the preparation of virus-safe pharmaceutical compositions
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
JP4536194B2 (en) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 Stable injectable formulation
ES2357474T3 (en) * 2000-03-07 2011-04-26 Rush-Presbyterian-St.Luke's Medical Center COMPOSITIONS AND ITS USE TO CATCH AND INACTIVATE PATHOGEN MICROBES AND SpermATOZIODS.
US6328987B1 (en) * 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
EP1449540A4 (en) * 2001-11-02 2007-01-10 Sekisui Chemical Co Ltd CYTOKINE INDUCTION SUBSTANCE AND CYTOKINE INDUCTION INSTRUMENT
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
MY188369A (en) * 2009-05-29 2021-12-06 Filligent Ltd Composition for use in decreasing the transmission of human pathogens
RU2431489C1 (en) * 2010-05-25 2011-10-20 Федеральное государственное учреждение "Российский научный центр рентгенорадиологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "РНЦРР Росмедтехнологий") Method of treating chronic inflammatory bowel diseases
CN104271142B (en) * 2012-03-01 2017-07-04 福斯特斯特林研究公司 The topical gel of PROTEIN C end (ACT) peptide is connected containing α
JP6081156B2 (en) * 2012-11-15 2017-02-15 アルケア株式会社 Hydrogel
DE102012222365A1 (en) 2012-12-05 2014-06-05 Aesculap Ag Composition for use in the prophylaxis of post-surgical adhesions
CA2913115A1 (en) * 2013-06-09 2014-12-18 Efranat Ltd. Compositions comprising gc-macrophage activating factor and uses thereof
WO2018143911A1 (en) 2017-01-31 2018-08-09 Kimberly-Clark Worldwide, Inc. Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same
MX2023004631A (en) 2020-10-22 2023-07-20 Xequel Bio Inc Peptide formulations and ophthalmic uses thereof.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
JPS6061535A (en) * 1983-08-24 1985-04-09 エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト Pharmaceutical composition
JPS6069037A (en) * 1983-09-26 1985-04-19 Sunstar Inc External preparation for erythematosus
EP0139286B1 (en) * 1983-10-14 1991-08-21 Sumitomo Pharmaceuticals Company, Limited Prolonged sustained-release preparations
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
JPS60228422A (en) * 1984-04-26 1985-11-13 Suntory Ltd Stabilized preparation of physiologically active substance
JPS60260523A (en) * 1984-06-07 1985-12-23 Asahi Chem Ind Co Ltd Lyophilized drug composition of interferon

Also Published As

Publication number Publication date
DK164202C (en) 1992-10-19
NO169638C (en) 1992-07-22
FI870457L (en) 1987-08-06
IL81472A0 (en) 1987-09-16
FI870457A0 (en) 1987-02-03
IE59697B1 (en) 1994-03-23
JPS62209024A (en) 1987-09-14
KR870007698A (en) 1987-09-21
GR3002270T3 (en) 1992-12-30
ZA87793B (en) 1988-10-26
DE3603444A1 (en) 1987-08-06
NZ219169A (en) 1990-04-26
NO169638B (en) 1992-04-13
AU601712B2 (en) 1990-09-20
PT84243B (en) 1989-09-14
FI86144C (en) 1992-07-27
DK58387A (en) 1987-08-06
EP0231816B1 (en) 1991-05-29
NO870441D0 (en) 1987-02-04
HU196560B (en) 1988-12-28
ES2028796T3 (en) 1992-07-16
HUT43494A (en) 1987-11-30
PT84243A (en) 1987-03-01
CA1295242C (en) 1992-02-04
DK58387D0 (en) 1987-02-04
EP0231816A3 (en) 1987-09-23
DD284602A5 (en) 1990-11-21
IE870295L (en) 1987-08-05
NO870441L (en) 1987-08-06
AU6829287A (en) 1987-08-06
ATE63823T1 (en) 1991-06-15
DE3770280D1 (en) 1991-07-04
DK164202B (en) 1992-05-25
FI86144B (en) 1992-04-15
EP0231816A2 (en) 1987-08-12

Similar Documents

Publication Publication Date Title
ZA87793B (en) Formulations suitable for the stabilisation of alpha-interferon
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
CA2058428A1 (en) Analgesic formulations
ES2009216A6 (en) IL-1alpha derivatives and drugs.
AU7076887A (en) Nasal administration of drugs
ZA928170B (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
PT779805E (en) SUSTAINED LIBERTACATION OF PEPTIDES OF PHARMACEUTICAL COMPOSITIONS
DK0395329T3 (en) Composition in the form of a foam containing 5-aminosalicylic acid for intrarectal administration
IE781032L (en) Pharmaceutical compositions
IL79816A0 (en) Pharmaceutical composition comprising a drug-polymer matrix
AU1518492A (en) Pharmaceutical compositions for transcutaneous administration
DK305087A (en) BUPRENORPHIC CONTAINED PHARMACEUTICAL SUPPLY
IL78604A (en) Process for the preparation of homogeneous,pure alpha-interferon,alpha-interferon produced thereby and pharmaceutical compositions containing it
GB2021409A (en) Pharmaceutical composition
AU581855B2 (en) 1-(4'-alkylsulphonylphenyl)-2-amino-1, 3-propanediol n-substituted derivatives
IE56229B1 (en) 2-piperazinyl-or-homopiperazinyl-quinazoline derivatives their production and pharmaceutical compositions containing them
AU581856B2 (en) 1-(4'-alkylthiophenyl)-2-amino-1, 3-propanediol N-substituted derivatives
IL106289A (en) Phospholipid derivatives their preparation and pharmaceutical compositions containing them
GB1351437A (en) N-substituted amino acids having antiviral anti-inflammatory or anti-tumour activity
EP0355899A3 (en) Nucleotide derivatives
ES2091571T3 (en) NEW ACTIVE PEPTIDIC DERIVATIVES IN THE CELL ADHESION PROCESSES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ATE102934T1 (en) FLUORINATED FLAVONACETIC ACID.
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
ES2135424T3 (en) ORAL COMPOSITION BASED ON IBUPROFEN.
IT1241459B (en) Pharmaceutical compositions for the rectal administration of calcitonin.